2025. Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s662. DOI:https://doi.org/10.25251/t6v95c18.